LEEDS, England, April 29, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on the clinical progress of its lead oncology Live Biotherapeutic MRx0518. Update on MRx0518 Phase I/II combination ...
from PR Newswire: https://prn.to/2PDDYm3
No comments:
Post a Comment